 Hypothesis two: The presence of one or both single-nucleotide polymorphisms SNPs in the gene coding for the immunoregulatory enzyme indoleamine 2,3-dioxygenase 2 IDO2 improves the clinical outcomes of WBRT or the response to CQ co-treatment. 